Cardiorenal syndrome: The clinical cardiologists' perspective

CardioRenal Medicine

Volumn 1, Issue 1, 2011, Pages 13-22

  Chan, Eric J ^a   Dellsperger, Kevin C ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Cardiorenal syndrome; Chronic kidney disease; Coronary artery disease; Heart failure; Metabolic syndrome

Indexed keywords

EID: 84857223648     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000322820     Document Type: Review

References (41)

1. Guyton AC, Hall JE: Textbook of Medical Physiology. New York, Saunders, 2000.
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: 948-954.
4. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, ADHERE Scientific Advisory Committee and Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
5. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572-580.
6. Braunwald E, Libby P, Bonow R, Mann DL, Zipes DP: Braunwald's Heart Disease. Philadelphia, Saunders, 2008.
7. Ronco C, House AA, Haapio M: Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-962.
8. Benigni A, Remuzzi G: Endothelin antagonists. Lancet 1999; 353: 133-138.
9. Weisbord SD, Palevsky PM: Radiocontrast-induced acute renal failure. J Intensive Care Med 2005; 20: 63-75.
10. Sandler CM: Contrast-agent-induced acute renal dysfunction - is iodixanol the answer? N Engl J Med 2003; 348: 551-553.
11. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, Van-Fossen DB: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254-261.
12. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.
13. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.
14. Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, Bartorelli AL: Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010; 38: 438-444.
15. Koreny M, Karth GD, Geppert A, Neunteufl T, Priglinger U, Heinz G, Siostrzonek P: Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002; 112: 115-119.
16. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, ESCAPE Investigators and ESCAPE Study Coordinators: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294: 1625-1633.
17. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA: Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268-1274.
18. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-596.
19. Bock JS, Gottlieb SS: Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592-2600.
20. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase- associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-2543.
21. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
22. Herget-Rosenthal S, Marggraf G, Ḧsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A: Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122.
23. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
24. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
25. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
26. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
27. Annual Data Report. http://www.usrds.org/adr.htm (accessed October 20, 2010).
28. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA, Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators: Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110: 1890-1895.
29. Ashrith G, Lee V, Elayda MA, Reul RM, Wilson JM: Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol 2010; 106: 348-353.
30. Sunagawa G, Komiya T, Tamura N, Sakaguchi G, Kobayashi T, Murashita T: Coronary artery bypass surgery is superior to percutaneous coronary intervention with drug-eluting stents for patients with chronic renal failure on hemodialysis. Ann Thorac Surg 2010; 89: 1896-1900, discussion 1900.
31. Liang KV, Williams AW, Greene EL, Redfield MM: Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36(suppl ):S75-S88.
32. Francis G: Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clin J Med 2006; 73(suppl 2):S8-S13, discussion S30-S33.
33. Liu PP: Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 2008; 24(suppl B):25B-29B.
34. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246-253.
35. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
36. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM: Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009; 157: 271-277.
37. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA for the UNLOAD Trial Investigators: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683.
38. Effectiveness of Ultrafiltration in Treating People with Acute Decompensated Heart Failure and Cardiorenal Syndrome (the CARRESS Study). http://clinicaltrials.gov/ct2/show/NCT00608491 (accessed October 19, 2010).
39. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971.
40. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
41. Gottlieb SS: Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 2008; 5: 105-109.